NCT06908642

Evaluation the Safety of hemay005 Tablets

Evaluation of the Safety of Hemay005 Tablets in Multiple Doses and Different Administration Methods in Multiple Administrations for Chinese Adult Healthy Subjects in a Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 468 (actual)
• Sponsor: Anhui Hemay Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

Type	Name	Description
DRUG	Hemay005 tablet	Hemay005 is a small molecule PDE4 inhibitor.
DRUG	Placebo	Placebos are the same as drugs, but contain no Hemay005.

Timeline

• Start date: 2024-12-25
• Primary completion: 2025-06-03
• Completion: 2025-06-03
• First posted: 2025-04-03
• Last updated: 2025-12-09

Locations

1 site across 1 country: China